文献速递心力衰竭与心肌病

沙库巴曲/缬沙坦治疗儿童心力衰竭:PANORAMA-HF随机双盲多中心试验

Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial.
PubMed 文献 · Circulation · 2024-09-25

PANORAMA-HF试验将375例因系统性左室收缩功能障碍导致心衰的1月龄至<18岁儿童随机分配至沙库巴曲/缬沙坦组或依那普利组,随访52周。主要终点为全局排名终点,结果显示沙库巴曲/缬沙坦未优于依那普利(Mann-Whitney概率0.52,95%CI 0.47-0.58,P=0.42)。两组在NYHA/Ross分级、PGIS、NT-proBNP等指标上均有临床意义的改善,安全性可接受。

要点

  • 沙库巴曲/缬沙坦在儿童心衰中未显示优于依那普利的疗效。
  • 两组治疗52周均有临床意义的改善,安全性相似。
  • 儿童心衰治疗中ARNI与ACEI的选择需个体化评估。

核心结论

  • 在因系统性左室收缩功能障碍导致心衰的儿童中,沙库巴曲/缬沙坦在预设全局排名终点上未优于依那普利。
  • 两种治疗在52周内均观察到临床有意义的改善,且安全性可接受。

研究设计与样本

  • 随机、双盲、多中心试验,纳入375例1月龄至<18岁因系统性左室收缩功能障碍导致心衰的儿童。
  • 患者随机分配至沙库巴曲/缬沙坦组(N=187)或依那普利组(N=188),随访52周。
  • 主要终点为全局排名终点,基于死亡、紧急心脏移植 listing、机械生命支持需求、心衰恶化、NYHA/Ross分级、PGIS和PedsQL体力功能域等临床事件从最差到最佳排序。
  • NT-proBNP从基线至52周的变化为探索性终点。

主要发现

  • 52周时,两组全局排名终点无显著差异(Mann-Whitney概率0.52,95%CI 0.47-0.58;Mann-Whitney比值比0.91,95%CI 0.72-1.14;P=0.42)。
  • 52周时,两组在NYHA/Ross分级、PGIS、PGIC和NT-proBNP上均观察到临床有意义的降低,组间无显著差异。
  • 不良事件发生率两组相似(沙库巴曲/缬沙坦88.8%,依那普利87.8%),沙库巴曲/缬沙坦的安全性可接受。

临床怎么用

  • 对于因系统性左室收缩功能障碍导致心衰的儿童,沙库巴曲/缬沙坦可作为依那普利的替代选择之一,但疗效未显示优于依那普利。
  • 治疗选择应综合考虑患者具体情况,两者均能带来临床改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF) with reduced left ventricular ejection fraction. It has not been rigorously compared with angiotensin-converting enzyme inhibitors in children. PANORAMA-HF (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) is a randomized, double-blind trial that evaluated the pharmacokinetics and pharmacodynamics (PK/PD), safety, and efficacy of sacubitril/valsartan versus enalapril in children 1 month to <18 years of age with HF attributable to systemic left ventricular systolic dysfunction (LVSD). METHODS: Children with HF attributable to LVSD were randomized to sacubitril/valsartan versus enalapril to assess the efficacy and safety of sacubitril/valsartan at 52 weeks of follow-up. The primary end point of the study was to determine whether sacubitril/valsartan was superior to enalapril for the treatment of pediatric patients with HF attributable to systemic LVSD, assessed using a primary global rank end point consisting of ranking patients from worst to best on the basis of clinical events such as death, listing for urgent heart transplant, mechanical life support requirement, worsening HF, New York Heart Association (NYHA)/Ross class, Patient Global Impression of Severity (PGIS), and Pediatric Quality of Life Inventory physical functioning domain. The change from baseline to 52 weeks in NT-proBNP (N-terminal pro-B-type natriuretic peptide) was an exploratory end point. RESULTS: A total of 375 children (mean age, 8.1±5.6 years; 52% female) were randomized to sacubitril/valsartan (N=187) or enalapril (N=188). At week 52, no significant difference was observed between the 2 treatment arms in the global rank end point (Mann-Whitney probability, 0.52 [95% CI, 0.47-0.58]; Mann-Whitney odds, 0.91 [95% CI, 0.72-1.14]; P=0.42). At week 52, clinically meaningful reductions were observed in both treatment arms in NYHA/Ross, PGIS, Patient Global Impression of Change, and NT-proBNP, without significant differences between groups. Adverse events were similar between treatment arms (incidence: sacubitril/valsartan, 88.8%; enalapril, 87.8%), and the safety profile of sacubitril/valsartan was acceptable in children. CONCLUSIONS: In this study, sacubitril/valsartan did not show superiority over enalapril in the treatment of children with HF attributable to systemic LVSD using the prespecified global rank end point. However, both treatment arms showed clinically meaningful improvements over 52 weeks. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02678312.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Shaddy R, Burch M, Kantor PF, et al. Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial. Circulation. 2024. PMID: 39319469. doi:10.1161/CIRCULATIONAHA.123.066605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。